Skip to main content

Table 1 Characteristics of 81MM patients according to their HCV status

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Items No. of patients (%) P value
Ab (-)ve No. = 66 (81.5%) Ab (+)ve/PCR (-)ve No. = 9 (11.1%) Ab (+)ve/PCR (+)ve No. = 6 (7.4%)
Age > 65 years 3 (4.5%) 2 (22.2%) 0 (0.0%) 0.095
Gender Male 30 (45.5%) 5 (55.6%) 4 (66.7%) 0.545
Female 36 (54.5%) 4 (44.4%) 2 (33.3%)
Serum M-protein:
 FLC 2 (3.0%) 0 (0.0%) 0 (0.0%) 0.806
 IgAK 3 (4.5%) 0 (0.0%) 0 (0.0%)
 IgAL 1 (1.5%) 0 (0.0%) 0 (0.0%)
 IgGK 50 (75.8%) 9 (100.0%) 6 (100.0%)
 IgGL 10 (15.2%) 0 (0.0%) 0 (0.0%)
ISS stage:
 I 14 (21.2%) 0 (0.0%) 0 (0.0%) 0.114
 II 24 (36.4%) 7 (77.8%) 3 (50.0%)
 III 28 (42.4%) 2 (22.2%) 3 (50.0%)
β2m ≥ 3.5 mg/L 12 (25.5%) 3 (37.5%) 0 (0.0%) 0.310
Albumin < 3.5 g/L 38 (58.5%) 8 (88.9%) 4 (66.7%) 0.205
Hemoglobin < 10 g/dL 31 (47.0%) 6 (66.7%) 1 (16.7%) 0.164
Platelets < 100 × 109/L 7 (10.6%) 3 (33.3%) 0 (0.0%) 0.096
Serum calcium ≥ 12.0 mg/dL 51 (96.2%) 9 (100.0%) 5 (83.3%) 0.762
Serum creatinine ≥ 2.0 mg/dL 58 (89.2%) 6 (66.7%) 6 (100.0%) 0.100
Response to MM treatment:
 CR 10 (15.2%) 0 (0.0%) 3 (50.0%) 0.100
 VGPR 10 (15.2%) 0 (0.0%) 0 (0.0%)
 PR 23 (34.8%) 7 (77.8%) 2 (33.3%)
 PD 13 (19.7%) 1 (11.1%) 0 (0.0%)
 ST 10 (15.2%) 1 (11.1%) 1 (16.7%)
  1. HCV hepatitis C virus, FLC free light chain, β2m beta-2-microglobulin, ISS International Staging System, ALT alanine transaminase, AST aspartate aminotransferase, T.bil total bilirubin, CR complete remission, VGPR very good partial response, PR partial response, PD progressive disease, ST stationary disease